trending Market Intelligence /marketintelligence/en/news-insights/trending/1q9t3LmedwDKpkYpIUHgPA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Merck's Alzheimer drug study triggers $10M milestone payment to Bionomics

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Merck's Alzheimer drug study triggers $10M milestone payment to Bionomics

Merck & Co. Inc. initiated a clinical trial for a novel cognition drug candidate, triggering a $10 million milestone payment to Bionomics Ltd.

Merck and Bionomics entered a research and license agreement in June 2014 to develop candidates to treat cognitive dysfunction associated with Alzheimer's disease.

Under the agreement, Merck is responsible for funding all early-stage and clinical development of any candidate within the collaboration and worldwide commercialization.

Meanwhile, Bionomics received $20 million in upfront payments and is eligible for up to an additional $506 million for predefined research and clinical development milestones, plus eventual undisclosed royalties on any product sales.